| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 12/20/2001 | WO2001096603A2 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | WO2001096547A2 Human kinases |
| 12/20/2001 | WO2001096546A2 Protein phosphatases |
| 12/20/2001 | WO2001096334A2 Heteroarylalkanoic acids as integrin receptor antagonists |
| 12/20/2001 | WO2001096310A1 Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
| 12/20/2001 | WO2001096308A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| 12/20/2001 | WO2001096307A2 Cycloalkyl alkanoic acids as integrin receptor antagonists |
| 12/20/2001 | WO2001095928A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | WO2001095859A2 Novel heterocyclic analogs of diphenylethylene compounds |
| 12/20/2001 | WO2001095785A2 Modulation of immune response and methods based thereon |
| 12/20/2001 | WO2001088108A8 Neuronal serine-threonine protein kinase |
| 12/20/2001 | WO2001066550A3 Compounds for pdt |
| 12/20/2001 | WO2001002552A3 Double transgenic animals as models for neurodegenerative disease |
| 12/20/2001 | WO2000072832A3 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts |
| 12/20/2001 | WO1997049394A3 Sold oral dosage forms of valsartan |
| 12/20/2001 | US20010053363 Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors |
| 12/20/2001 | US20010053357 Peptide having an amino acid sequence corresponding to an amino acid sequence of a V-domain of a receptor for advanced glycation endproduct. |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | DE10024171A1 Neuronale Serin-Threonin-Protein-Kinase Neuronal serine threonine protein kinase |
| 12/20/2001 | CA2412579A1 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2410171A1 Novel heterocyclic analogs of diphenylethylene compounds and uses thereof |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/19/2001 | EP1163902A2 Transdermal preparation containing hydrophilic or salt-form drug |
| 12/19/2001 | EP1163238A1 Chemokine recpetor binding heterocyclic compounds |
| 12/19/2001 | EP1163214A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 12/19/2001 | EP1163208A2 Caspase inhibitors and uses thereof |
| 12/19/2001 | EP1163017A1 Muscle tissue engineering |
| 12/19/2001 | CN1327382A Improved formulation for topical non-invasive application in vivo |
| 12/18/2001 | US6331615 Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand) |
| 12/18/2001 | US6331556 Benzofuran-4-carboxylic acid amide derivatives used as phosphodiesterase iv or tumor necrosis factor inhibitors |
| 12/18/2001 | US6331433 Human T cell leukemia cell line designated D1.1 |
| 12/18/2001 | US6331298 Wound healing and treatment of fibrotic disorders |
| 12/13/2001 | WO2001094555A1 Method for obtaining characterised muscle-derived cell populations and uses |
| 12/13/2001 | WO2001094415A2 Nuclear hormone receptor |
| 12/13/2001 | WO2001094414A2 THE HUMAN VOLTAGE GATED SODIUM CHANNEL β-1A SUBUNIT AND METHODS OF USE |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094369A2 Heterocycle derivatives and methods of use for treating anthrax infection |
| 12/13/2001 | WO2001094351A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | WO2001093911A2 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | WO2001093890A2 Botulinum toxin implant |
| 12/13/2001 | WO2001093888A2 A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093827A2 Neurotoxin implant |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001029017A3 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF η-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |
| 12/13/2001 | WO2001027136A3 Peptides which stimulate the immune response and tissue regeneration |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | US20010051656 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 12/13/2001 | US20010051602 Alzheimer's disease; adjust apolipoprotein concentration |
| 12/13/2001 | CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | CA2411762A1 Method for obtaining characterised muscle-derived cell populations and uses |
| 12/13/2001 | CA2411428A1 A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs |
| 12/13/2001 | CA2411069A1 The human voltage gated sodium channel .beta.-1a subunit and methods of use |
| 12/13/2001 | CA2409392A1 Intracellular signaling proteins |
| 12/13/2001 | CA2409268A1 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | CA2409123A1 Heterocycle derivatives and methods of use |
| 12/13/2001 | CA2409015A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | CA2408748A1 Nuclear hormone receptor |
| 12/12/2001 | EP1161429A2 Heterocyclic compounds as adenosine deaminase inhibitors |
| 12/12/2001 | EP1161422A1 Amine derivatives as protease inhibitors |
| 12/12/2001 | EP1161419A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 12/12/2001 | EP1161415A2 N-cyanomethylamides as protease inhibitors |
| 12/12/2001 | EP1161232A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists |
| 12/12/2001 | EP0889730B1 Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| 12/12/2001 | CN1326456A 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives |
| 12/12/2001 | CN1326348A Riluzole and alpha-tocopherol combination |
| 12/12/2001 | CN1325722A Chinese medicine for treating diabetes and neurovascular lesion of both feet and its preparing process |
| 12/11/2001 | US6329511 Humanized mouse af2 immunoglobulin having specific amino acid sequences; treatment of autoimmune diseases |
| 12/11/2001 | US6328708 Device for controlled anaesthesia, analgesia and /or sedation |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092526A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | WO2001092479A2 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | WO2001092333A2 Use of adnf for enhancing learning and memory |
| 12/06/2001 | WO2001092330A2 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation |
| 12/06/2001 | WO2001092308A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092273A2 Benzenedicarboxylic acid derivatives |
| 12/06/2001 | WO2001092230A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091780A1 Neuroprotective peptides |
| 12/06/2001 | WO2001091778A2 Compositions for treating neck and shoulder discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091771A2 Compositions for treating back and leg discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091766A2 Compositions for treating hand and wrist discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091744A1 Methods of treating androgen deficiency in men using selective antiestrogens |
| 12/06/2001 | WO2001025257A3 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 12/06/2001 | WO2001016345A3 Sequence-specific dna recombination in eukaryotic cells |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001001972A3 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 12/06/2001 | WO2000077206A3 The myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | US20010049435 Myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | CA2617253A1 Synergistic agents for enhancing tissue repair |
| 12/06/2001 | CA2410912A1 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410758A1 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation |
| 12/06/2001 | CA2410735A1 Use of adnf for enhancing learning and memory |
| 12/06/2001 | CA2410684A1 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | CA2410489A1 Human kcnq5 potassium channel, methods and compositions thereof |